NRXS · XBRL financial data

Neuraxis financial statements, every quarter

The same tables from 13 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (NRXS's year ends in late December)

In thousands of dollars	Q2 FY23Aug 11, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q1 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Dec 31, 2026
Revenue	—	477	531*	—	—	year only	—	—	—	year only	—	—
Revenue from contracts with customers	—	477	531*	612	667	761*	896	894	811	968*	1,608	—
Cost of goods and services sold	—	67	72*	73	97	105*	139	147	135	142*	218	—
Gross profit	—	410	459*	538	570	656*	756	747	676	826*	1,390	—
Research and development	—	45	(2)*	54	72	74*	61	58	131	146*	100	—
General and administrative	—	3,323	2,012*	2,628	2,053	1,951*	2,857	2,265	1,883	1,812*	2,206	—
Operating income (loss)	—	(3,022)	(1,623)*	(2,207)	(1,651)	(1,467)*	(2,295)	(1,718)	(2,100)	(1,717)*	(1,741)	—
Interest expense	—	103	23*	81	65	2*	2	13	30	29*	26	—
Other income (expense)	—	(1,882)	(3,690)*	(711)	(104)	19*	16	27	(23)	8*	(21)	—
Net income (loss)	—	(4,904)	(5,313)*	(2,918)	(1,755)	(1,448)*	(2,279)	(1,690)	(2,123)	(1,709)*	(1,761)	—
Earnings per share, basic USD per share	—	(1.35)	—	(0.42)	(0.25)	—	(0.33)	(0.22)	(0.24)	(0.16)*	(0.18)	—
Earnings per share, diluted USD per share	—	(1.35)	—	(0.42)	(0.25)	—	(0.33)	(0.22)	(0.24)	(0.16)*	(0.18)	—
Weighted average shares, basic thousands of shares	—	3,626	—	6,921	7,172	—	7,464	8,521	9,878	10,430*	10,948	—
Weighted average shares, diluted thousands of shares	—	3,626	—	6,921	7,172	—	7,464	8,521	9,878	10,430*	10,948	—

Balance sheet

CSV

Fiscal quarters (NRXS's year ends in late December)

In thousands of dollars	Q2 FY23Aug 11, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q1 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Dec 31, 2026
Cash and cash equivalents	—	761	79	1,765	261	3,697	2,005	5,988	4,377	4,965	7,079	—
Accounts receivable	—	132	73	147	53	245	244	129	109	196	385	—
Inventory	—	35	21	43	22	44	37	131	110	257	238	—
Prepaid and other current assets	—	39	70	156	296	280	255	370	392	315	441	—
Total current assets	—	967	243	2,112	632	4,266	2,541	6,619	4,988	5,733	8,143	—
Property and equipment, net	—	80	89	95	94	90	104	101	85	76	68	—
Right-of-use asset	—	78	70	323	298	285	271	257	277	262	245	—
Total assets	—	1,236	509	2,633	1,143	4,758	3,030	7,088	5,776	6,404	8,746	—
Accounts payable	—	567	1,204	1,118	962	597	535	465	886	139	305	—
Accrued liabilities	—	280	401	1,311	1,170	1,578	1,371	1,653	1,956	2,393	2,261	—
Total current liabilities	—	2,258	1,886	7,594	2,664	2,433	2,101	2,347	3,147	2,792	2,814	—
Total deposits	—	69	75	82	85	33	38	32	37	29	30	29
Lease liability, non-current	—	39	27	298	273	256	239	220	220	203	184	—
Total liabilities	—	2,297	1,913	7,892	2,937	2,690	2,771	2,835	3,491	3,005	2,998	—
Accumulated deficit	—	(43,245)	(48,558)	(53,596)	(55,352)	(56,800)	(59,078)	(60,769)	(62,892)	(64,600)	(66,362)	—
Total stockholders' equity	—	(1,061)	(1,403)	(5,258)	(1,794)	2,068	258	4,253	2,285	3,399	5,748	—
Total liabilities and equity	—	1,236	509	2,633	1,143	4,758	3,030	7,088	5,776	6,404	8,746	—
Common shares outstanding (cover page) thousands of shares	4,981	5,290	6,595	6,842	6,980	6,648	7,216	9,859	10,653	11,188	12,384	12,558

Cash flows

CSV

Fiscal quarters (NRXS's year ends in late December)

In thousands of dollars	Q2 FY23Aug 11, 2023	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q1 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Dec 31, 2026
Net income (loss)	—	(4,904)	(5,313)*	(2,918)	(1,755)	(1,448)*	(2,279)	(1,690)	(2,123)	(1,709)*	(1,761)	—
Stock-based compensation	—	—	year only	0*	0*	0*	106	173*	161*	157*	329	—
Depreciation and amortization	—	10*	10*	11*	9*	7*	6	13*	16*	—	—	—
Net cash from operating activities	—	(2,816)*	(2,630)*	(1,615)*	(1,393)*	(1,758)*	(1,604)	(1,467)*	(1,428)*	(1,934)*	(1,230)	—
Purchases of property and equipment	—	3*	16*	9*	4*	0*	18	7*	0*	6*	—	—
Net cash from investing activities	—	(43)*	(16)*	(9)	(4)	0*	(18)	(7)	0	(106)*	—	—
Proceeds from issuing common stock	—	—	(617)*	—	—	—	—	—	0*	2,728*	2,990	—
Net cash from financing activities	—	3,569*	1,963*	3,307*	(107)*	5,194*	(70)	5,458*	(184)*	2,628*	3,343	—
Net change in cash	—	710*	(683)*	1,684*	(1,504)*	3,436*	(1,692)	3,983*	(1,611)*	588*	2,114	—

Compare with peers

SIC 3845 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3845 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Neuraxis	8,322	1,929	(1,030)*	12.6M	—	Q2 FY26 10-QJun 30, 2026
Allurion Technologies	5,056	2,947	(3,221)	15.0M	1.6 quarters	Q1 FY26 10-QMar 31, 2026
Dror Ortho-Design	94	not reported	(305)*	977.0M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Positron	357	112	(1,050)*	32.8M	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Vivos Therapeutics	1,774	5,153	(3,148)*	20.1M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
United Health Products	24	0	(138)*	262.7M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
Neuroone Medical Technologies	2,048	1,973	(1,082)*	9.1M	1.9 quarters	Q3 FY26 10-QJun 30, 2026
Precision Optics	9,841	8,774*	(649)*	11.0M	15.2 quarters	Q4 FY26 10-KJun 30, 2026
Encision	72	1,528	(127)*	16.9M	0.6 quarters	Q2 FY26 10-QSep 30, 2025

Not investment advice. Not affiliated with the U.S. SEC.